Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$0.00
C$11.77
C$26.00
C$2.15BN/A229,895 shs4.61 million shs
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.17
+7.6%
$4.88
$3.96
$9.85
$2.29B0.282.63 million shs3.03 million shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4124,350 shs237,144 shs
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$0.38
$0.38
$0.26
$1.30
$67.96M0.747,701 shs29,889 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-2.93%+12.72%+22.61%-18.06%-10.86%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+1.72%+74.13%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.7721 of 5 stars
1.92.00.04.04.13.30.6
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3136 of 5 stars
0.00.00.04.20.60.80.0
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00
N/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.86
Reduce$7.4220.30% Upside
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PYR, AUP, BHC, and CARA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
4/7/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform$9.00 ➝ $8.50
(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$57.59M0.00N/A6.75C$2.59 per share0.00
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.63B0.24$8.01 per share0.77($0.89) per share-6.93
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
$14.63M4.65N/AN/A$0.07 per share5.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A-C$1.48N/AN/AN/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.32N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
-$24.74M-$0.11N/AN/A-233.18%-194.66%-68.91%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
2.69
11.93
11.02
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.26
0.86
0.78

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
0.41%

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.12%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
47.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
300128.40 millionN/ANot Optionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.03 millionOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
PyroGenesis Canada Inc. stock logo
PYR
PyroGenesis Canada
2,020178.88 million93.59 millionNot Optionable

Recent News About These Companies

PyroGenesis successfully operates fumed silica reactor pilot plant
PyroGenesis receives $1.85M under Drosrite contract
PyroGenesis Canada Tackles PFAS with Plasma Technology
PyroGenesis Canada Optimistic About U.S. Policy Changes
PyroGenesis Partners with Global Steel Giant
Stocks in play: PyroGenesis Inc.
PyroGenesis Inc. Rebrands and Relocates Headquarters

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.16 +0.44 (+7.59%)
As of 02:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYR

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. It offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. The company also provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montréal, Canada.